HAHelena D. Aicher

Helena D. Aicher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helena D. Aicher has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond dose. Perceived group support as a person-level predictor of emotional breakthrough and psychological insight during DMT–harmine administration

    by Jonas Schlomberg, John Smallridge, Joëlle Dornbierer, Klemens Egger, Helena Aicher, Daniel Meling, Florian Wittwer, Javier Redondo, Jovin Mueller, Jasmine Ho, et al.

    Dose-escalation studies with dimethyltryptamine (DMT) show robust increases in emotional breakthrough, mystical experience, and psychological insight at higher doses, but with substantial inter-individual variability, suggesting factors beyond pharmacology shape response profiles. Growing evidence points to the clinical relevance of social factors, especially in group-based psychedelic therapy. Using data from a randomized-controlled trial, we investigated oromucosal DMT-harmine administration in a group setting and identified a three-layer architecture of acute psychedelic experience. First, dose scaled all three primary subjective outcomes. Second, perceived group support, reflecting stable between-person differences rather than session-to-session fluctuations, accounted for a substantial share of dose-independent between-subject variance in emotional breakthrough and psychological insight, though not in mystical-type experience. Third, pre-session affective personality, indexed by an approach-withdrawal composite, predicted group appraisal, with more approach-oriented profiles linked to more favorable perceptions of the group context. We situate these findings within the current research landscape and discuss the clinical implications of this three-layer framework for acute psychedelic experience.

  • N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state

    by Maria Niedernhuber, Dila Suay, Bigna Lenggenhager, Michael Müller, Milan Scheidegger, Dario Dornbierer, Helena Aicher

    Background: Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyond temporal variability, it is an open question whether psychedelics impact the characteristics of transient neural state sequences themselves. Aims: Our goal was to assess how an ayahuasca-inspired formulation (intranasal N,N-Dimethyltryptamine (DMT) and buccal harmine) modulates parameters of neural state sequences close to the peak of the psychedelic state. Methods: In a double-blind, randomised, placebo-controlled Electroencephalography (EEG) study, participants ( n = 25) were administered the following interventions on separate testing days: (1) a DMT/harmine formulation; (2) harmine alone and (3) a placebo. We used EEG microstate analysis to compare the neural dynamics between the three conditions. Results/Outcomes: Compared to harmine and placebo, DMT/harmine was linked to reduced microstate duration but increased microstate occurrence and complexity. Higher first-order Markov statistics revealed that transition sequences became less random when DMT/harmine was administered. Conclusions/Interpretation: Our finding that DMT/harmine is associated with more complex and predictable neural state sequences as well as accelerated state transitions is consistent with models of increased metastability and signal diversity. By revealing a more diverse repertoire of neural state sequences under DMT/harmine, our findings improve our understanding of neural dynamics in psychedelic states. Clinical trial registration: Neurodynamics of prosocial emotional processing following serotonergic stimulation with N,N-DMT and harmine in healthy subjects. https://clinicaltrials.gov/ct2/show/NCT04716335 .

  • Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety

    by Wolfgang Emanuel Zürrer, Johann Liesner, David Brüschweiler, Helena D. Aicher, Milan Scheidegger, Benjamin Victor Ineichen

    Salvinorin A, the principal psychoactive constituent of Salvia divinorum , is a highly selective κ-opioid receptor agonist and a rare example of a κ-opioid receptor-mediated psychedelic drug. Preclinical work of salvinorin A has shown promising effects in neuropsychiatric animal models. However, human studies remain heterogeneous and fragmented, highlighting the need for synthesis. Thus, we conducted a systematic review to synthesize available human studies of salvinorin A, with a focus on pharmacokinetics, pharmacodynamics, safety, and longer-term effects. We searched PubMed, Web of Science, and EMBASE from inception to January 18, 2026. We included 12 clinical trials comprising 174 participants. Most studies enrolled medically healthy, hallucinogen-experienced volunteers and administered salvinorin A by inhalation (0.375–21 µg/kg or 0.2–12 mg). Pharmacokinetic profiles were characterized by rapid onset within seconds, peak effects at 1–2 minutes, and resolution within 30 minutes, consistent with fast absorption and clearance. Sublingual administration in two studies produced slower onset and longer duration, whereas oral dosing was inactive in one study. No serious adverse events were reported. Physiological parameters were largely stable, with occasional mild increases in blood pressure/heart rate. Acute psychological effects included disorientation, anxiety, and distress in subsets of participants, alongside reports of positive subjective changes. Long-term adverse effects were rare, and abuse potential appeared low. Overall, salvinorin A exhibits a distinct human neuropsychopharmacological profile compared with serotonergic psychedelics. These findings support cautious further investigation in controlled studies. Further, salvinorin A can serve as a model for probing κ-opioid receptor-mediated alterations of consciousness in humans.

  • Open Access

    Combined DMT–harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers

    by Helena D. Aicher, Joëlle Dornbierer, Luzia Caflisch, Dila Suay, Michael J. Mueller, Hans-Peter Landolt, Boris B. Quednow, Milan Scheidegger, Dario Dornbierer

    Rationale and objectives: Negative self-referential emotions such as embarrassment and shame play a key role in the psychopathology of psychiatric disorders but are often insufficiently addressed by standard treatments. Psychedelics such as ayahuasca – an Amazonian plant decoction containing the psychedelic N,N-dimethyltryptamine (DMT) and harmala alkaloids, have been proposed to positively modulate self-referential processing. The aim of this study was to investigate the effects of an ayahuasca-inspired harmine+DMT formulation and harmine on embarrassment and shame. Methods: In this randomized, double-blind, placebo-controlled crossover trial (N = 28 healthy males), the effects of combined 100mg harmine and 100mg DMT (HAR/DMT), harmine alone (HAR), against placebo (PLA) on self-referential processing was investigated using a karaoke paradigm, where participants listened to recordings of their own singing (Self = S) and control vocal tracks (other bad = OB; other good = OG) and rated emotional responses. Acute emotions were assessed with visual analogue scales (items: pleasant, unpleasant, embarrassing, funny, and objective quality) and the Experiential Shame Scale (ESS). Results: HAR/DMT compared to placebo significantly reduced embarrassment in the Self condition (EMM=-16.83, p=.001), but not in the two other conditions (OB: EMM=-4.38, p=.628; OG: EMM= 2.14, p=.894). HAR/DMT–HAR or HAR–PLA contrasts for embarrassment were not significant for any condition. HAR/DMT compared to placebo reduced ESS global score (F(df)= 4.26(2, 54); p=.019) and ESS emotional subscale (F(df)=5.11(2, 54); p=.009), while harmine alone showed no significant effects. Conclusions: These findings suggest that HAR/DMT acutely modulates negative self-referential emotions and may, thus, offer a promising therapeutic approach, which should be further investigated in clinical populations.

  • Open Access

    Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study

    by Klemens Egger, Robert Bozsak, Helena D. Aicher, Hasan Sari, Sandra N. Poetzsch, Axel Rominger, Chantal Martin-Soelch, John W. Smallridge, Dario Dornbierer, Boris B. Quednow, et al.

    Classical psychedelics such as N,N -dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging studies have characterized effects of DMT on functional connectivity and electroencephalography its impact on cerebral energy metabolism remains largely unexplored. We assessed the cerebral metabolic rate for glucose consumption (CMRglc) with [ 18 F]fluorodeoxyglucose positron emission tomography ([ 18 F]FDG-PET) and linear graphic analysis following buccal DMT + harmine (90 mg DMT, 120 mg harmine) versus placebo in a single-blind, crossover design in 14 healthy males. Scans were acquired during peak drug effects (100–170 min post-administration). Global CMRglc increased by 12.5% under DMT+harmine versus placebo ( t = 2.58, p = 0.011). Vertex- and network-wise analyses revealed widespread cortical increases, particularly in higher-order brain networks. Exploratory analyses found a significant positive correlation between global CMRglc and harmine plasma levels, but not with DMT plasma levels, subjective intensity ratings. A psychedelic dose of DMT + harmine globally increased cerebral glucose metabolism, recapitulating a classic finding for psilocybin, and suggesting a potential metabolic signature of the psychedelic state. Clinical trial registry name and URL incl. registration number: Molecular Imaging Study of Harmine/DMT: a Basic Research Approach (HaD-PET) https://clinicaltrials.gov/study/NCT06252506 .


  • Open Access

    Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians

    by Kristian Beichmann, Polina Catzeflis, Helena D. Aicher, Federico Seragnoli, Abigail Calder, Adam Amrani, Gregor Hasler

    Background: The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy- N -methamphetamine (MDMA). Objectives: The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH). Design: Swiss PAT practices were examined using an anonymous survey of physicians providing PAT. Questions included physicians’ backgrounds, training, therapeutic orientation, treatment protocols, patient characteristics, and perceived benefits. Methods: Participants were recruited from PAT professional associations and the research team network. Forty-one physicians providing PAT under FOPH exemptions contributed to the survey. Results: Respondents used PAT primarily for depression, anxiety, post-traumatic stress disorder (PTSD), and chronic pain. Most physicians practiced in private practices, private outpatient clinics or shared practices (82%), with a minority in hospitals (18%). The most reported labels when providing PAT were body-oriented (61%), psychodynamic (59%), and eclectic (54%) approaches. Respondents provided PAT using psilocybin (85%), MDMA (71%), and LSD (65.9%). Choice of first substance was linked to diagnosis, with physicians preferring psilocybin for depression (54%) and substance use disorder (46%) and MDMA for PTSD (86%) and anxiety disorders (54%). A total of 90% reported always playing music during psychedelic sessions. Loss of orientation in time and space, feeling too cold, anxiety, and nausea where the most frequent adverse effects of PAT. 95% had emergency medication available, on average used during 2.4% of sessions. Challenges included legal constraints, high patient expectations, and financial barriers. Group therapy was common, with 9% reporting providing only group sessions, 42% providing both individual and group settings, and 47% providing only individual sessions. Only 9% reported never using co-sitters. Conclusion: This study offers valuable insights into the methods and experiences of physicians providing PAT in a legal clinical context, giving insight into the considerable variety of clinical methods. Cultural and regulatory differences may limit generalizability.


  • Psychedelika in der Psychotherapie: Von der pharmakologischen Wirkung zur transdiagnostischen Veränderung

    by Susanne Prinz, Helena Aicher

    Zusammenfassung: Die Psychedelika-assistierte Therapie (PAT) hat sich in den letzten Jahren zu einem der dynamischsten Forschungsfelder der Psychiatrie entwickelt. Während die beste Evidenz bisher für depressive Störungen und posttraumatische Belastungsstörungen vorliegt, wird PAT zunehmend auch bei anderen nicht-psychotischen Störungen untersucht. Jenseits der Symptomlinderung rückt die Bedeutung transdiagnostischer Prozesse wie Verbesserung von Akzeptanz, Verbundenheitserleben und kognitiver Flexibilität in den Mittelpunkt. Dieser Übersichtsartikel fasst die aktuellen Erkenntnisse zum therapeutischen Einsatz von Psychedelika, MDMA und Ketamin zusammen. Er beleuchtet neurobiologische, psychologische und kontextuelle Wirkmechanismen, stellt die bisherige klinische Evidenz dar und diskutiert Risiken, Kontraindikationen sowie konzeptionelle Herausforderungen der klinischen Anwendung. Die vorliegenden Daten zeigen eine gute Verträglichkeit unter professioneller Begleitung und deutliche Hinweise auf Wirksamkeit bei Depression und PTBS. Erste Studien deuten zudem auf Potenziale bei Angst-, Zwangs- und Essstörungen und damit das transdiagnostische Potential hin. PAT eröffnet neue Perspektiven für Psychotherapie, fordert aber zugleich eine Erweiterung des therapeutischen Verständnisses über diagnostische Kategorien hinaus.

  • Open Access

    The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies

    by Wolfgang Emanuel Zürrer, Lionel Wettstein, Helena D. Aicher, Milan Scheidegger, Benjamin Victor Ineichen

    Background: Salvinorin A, the main psychoactive compound of Salvia divinorum, is a potent and selective kappa opioid receptor agonist. While human clinical trials remain limited, animal studies suggest potential therapeutic applications in neurological and psychiatric disorders. This systematic review and meta-analysis aims to synthesize these preclinical findings, addressing three questions: (1) What is the therapeutic potential of salvinorin A in animal models of neurological and psychiatric disorders? (2) What are its toxic effects on behaviour, cognition, and physiological function? (3) What are its pharmacokinetic characteristics? Methods: A systematic search of Medline, Web of Science, and EMBASE for studies published up to June 28, 2024, identified 1718 publications, of which 82 were included in the qualitative synthesis and 10 in the meta-analysis. Results: Salvinorin A has been tested in animal models of pain, cerebrovascular insults, addiction, and depression. It exhibited anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects. Findings on depression were inconsistent, with both antidepressant and depressogenic outcomes reported. Toxicity data indicate anxiogenic effects and motor and cognitive impairment, with minimal impact on vital parameters. Applied doses ranged from 0.1–10 mg/kg, with lower doses in stroke models. Pharmacokinetic data show rapid onset, fast peak, and a half-life of approximately one hour. Sixteen structurally distinct salvinorin A analogues were identified with potentially improved safety and pharmacokinetic profiles. Conclusion: Our findings support the therapeutic potential of salvinorin A for pain, addiction, and stroke, though its side effect profile may limit clinical application. The development of novel analogues could address these challenges.


  • Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation

    by Dila Suay, Helena D Aicher, Berit Singer, Michael J Mueller, Alen Jelusic, Lionel Calzaferri, Paul Springfeld, Dario A Dornbierer, Milan Scheidegger

    Background: While psychedelics are often claimed to enhance creativity, their precise effects on distinct stages of creative cognition remain poorly understood. This study investigated the acute effects of an ayahuasca-inspired formulation combining N,N-dimethyltryptamine (DMT) and harmine (DMT/HAR), as well as harmine alone (HAR), on micro-level (divergent/convergent thinking) and macro-level (creative process dynamics) creativity. Methods: In a double-blind, placebo-controlled, within-subject design, 30 healthy male participants completed three sessions (DMT/HAR, HAR, placebo). Micro-level creativity was assessed using the picture concept task (convergent thinking) and alternative uses task (divergent thinking). Macro-level dynamics were examined through a real-world painting task using the creative process report diary, which captured dynamic stage transitions. Subjective experiences were also recorded to explore their predictive value for creativity. Results: DMT/HAR significantly impaired convergent thinking, particularly in individuals with higher baseline reasoning. Divergent thinking showed no overall effect but revealed trend-level reductions in fluency and elaboration under DMT/HAR. At the macro-level, both DMT/HAR and HAR reduced incubation-related transitions, while DMT/HAR uniquely decreased transitions from incubation to illumination, suggesting altered pathways to insight. Subjective experiences such as altered meaning perception and increased insightfulness selectively predicted divergent, but not convergent, thinking outcomes. Conclusions: This study demonstrates that the effects of DMT/HAR on creativity are not uniform. By capturing real-world creative behavior through an ecologically valid painting task, this study offers the first evidence that psychedelics influence not only creative cognition but also the dynamic processes that give rise to it. These findings highlight the importance of integrating cognitive, phenomenological and process-level perspectives to better understand creative thinking under altered states. Future research should further investigate how individual differences in subjective experience and cognitive style modulate the unfolding of creative processes under psychedelics.

  • Open Access

    Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects

    by Helena D Aicher, Ilhui A Wicki, Daniel Meling, Michael J Mueller, Dario A Dornbierer, Milan Scheidegger

    Background: Mindfulness and compassion are therapeutically relevant and can be increased through different forms of meditation practices. However, meditation practice needs time and commitment. These resources are often limited in patients with mood disorders. Therefore, efficacious remedies that increase mindfulness and compassion could provide therapeutic options. This study aimed to investigate the relationship between psychedelic experiences induced by an ayahuasca-inspired N,N-dimethyltryptamine (DMT)/harmine formulation on mindfulness and compassion in healthy subjects. Methods: This study applies a randomized, double-blind, placebo-controlled within-subjects design in a laboratory setting with 31 healthy participants. Each subject received a formulation comprising DMT + harmine, harmine + placebo, and placebo only on three different study days. Primary outcomes were mindfulness (MINDSENS) and compassion (SOCS). Results: A significant effect of the drug on mindfulness ( p < 0.05, F = 3.41), self-compassion (SOCS-S; p < 0.01, F = 7.53), and compassion with others (SOCS-O; p < 0.05, F = 3.37) 1 day post-treatment was found. Significant differences between the high- and low-sensitivity groups were found for mindfulness ( p < 0.05, F = 6.54), self-compassion ( p < 0.05, F = 4.21), and compassion with others ( p < 0.05, F = 4.42). Conclusions: In line with previous studies on traditional botanical ayahuasca, our findings support the notion that the DMT/harmine formulation might have therapeutic potential through its ability to acutely enhance mindfulness and compassion. Continuing studies in therapeutic settings are needed to further elucidate the mechanisms of action of ayahuasca-inspired formulations.